A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

532

Participants

Timeline

Start Date

May 8, 2019

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Stage III Pancreatic Cancer
Interventions
DRUG

SOC

Standard of Care treatment

DEVICE

NanoKnife System

Irreversible Electroporation

Trial Locations (14)

10016

NYU Langone, New York

10032

Presbyterian Hospital, Columbia, New York

18045

St. Luke's University Health Network, Easton

28204

Atrium Health, Charlotte

30060

Wellstar Medical Group, Marietta

32608

University of Florida Health, Gainesville

33176

Miami Cancer Institute, Miami

40202

Norton Healthcare, Louisville

52242

University of Iowa Healthcare, Iowa City

55905

Mayo Clinic, Rochester, Rochester

60005

Northwest Community Hospital, Arlington Heights

63110

Barnes-Jewish Hospital, St Louis

75231

University of Texas-Southwestern, Dallas

92093

Moores Cancer Center, UC San Diego Health, La Jolla

Sponsors
All Listed Sponsors
lead

Angiodynamics, Inc.

INDUSTRY

NCT03899649 - A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer | Biotech Hunter | Biotech Hunter